Novo Nordisk will work with each group to create and promote programs that use a variety of hands-on education and intervention techniques to reach diabetes patients in Atlanta. According to a recent study commissioned by Novo Nordisk and conducted by the Institute for Alternative Futures, in 2010, 765,300 Atlanta residents (13.6%) had diagnosed or undiagnosed diabetes and 11.8% (90,050) of those had serious complications, such as visual impairment, renal failure, and leg amputation. The annual cost to the residents of Atlanta for diabetes was $6.8 billion in 2010. Further, forecasts project that by 2025, more than 1.3 million Atlanta residents will have diabetes at a total cost of $12.5 billion. Statewide, nearly 17.9% of Georgia residents are projected to have diabetes by 2025 at a cost of $19.5 billion.
"Novo Nordisk is proud to support community-based type 2 diabetes programs in Atlanta because they have the potential to help stem the tide of diabetes," said Lori Moore, Executive Director of Communications and Public Affairs at Novo Nordisk. "Novo Nordisk brings innovative treatments and devices to the diabetes community, but as an industry leader, we also have the opportunity and responsibility to provide resources to local organizations whose deep understanding of their constituency's needs can make a significant impact on the way patients manage their disease. We very much look forward to seeing the programs roll out and make a difference in the communities they serve."
In 2011, sponsorships have already been awarded in Philadelphia and Minneapolis and will also be awarded in Boston to inspire similar grassroots education programs. For more information about Novo Nordisk Community Care and to find local event listings and resources for people living with diabetes, go to NovoNordiskCommunityCare.com
About Novo Nordisk
|SOURCE Novo Nordisk|
Copyright©2010 PR Newswire.
All rights reserved